GlaxoSmithKline has won a contract with the UK’s NHS to supply its cervical cancer vaccine,
Cervarix.
The battle to supply a vaccine against cervical cancer for use across Britain has been won by GlaxoSmithKline (GSK).
Cervarix, the GSK vaccine, will be given to girls aged between 12 and 13, starting in September this year, and should prevent about 70 per cent of cervical cancers — saving 400 lives a year when the effect is fully felt.
Read more from The UK Times Online.
Let’s wait and see what Merck (maker of the other cervical cancer vaccine Gardasil) has to say about this.